Control for stochastic sampling variation and qualitative sequencing error in next generation sequencing analysis of KRAS actionable mutations  by Yeo, Jiyoun et al.
February 2016 Abstracts S53bisulﬁte converted and puriﬁed from 3.5ml plasma
samples utilizing a commercially available kit. In a case-
control design 149 specimens from lung cancer patients
and age-matched healthy individuals were evaluated.
The diagnostic performance was compared to the results
from a previously conducted training study on 151
specimens.
Data and Results: For the training study including 59 LC
subjects the performance of the marker panel reached
very high sensitivity (78–95%) at reasonable rates of false
positives (5–36%). The area under the receiver operating
characteristic (ROC) curve was AUC ¼ 0.91. This clinical
performance was conﬁrmed in a similar sized marker
validation study of an independent set of 149 patients. A
total of 49 LC cases and 100 age-matched clinical controls
were tested. At 95% speciﬁcity level sensitivity was 67%.
Sensitivity of 95% was observed at a speciﬁcity level of
62%. Sensitivitywas evenly high acrossmajor histological
types and stage groups. The AUC ¼ 0.94 observed in the
testing studywas not statistically different from the result
of the training set (p-value > 0.05).
Conclusions: The combined analysis of the two DNA
methylation markers SHOX2 and PTGER4 can be used to
detect lung cancer in plasma samples with very high
sensitivity at reasonable false positive rate. These ﬁnd-
ings were derived in a training study and conﬁrmed in
this marker validation study. The marker panel is being
used as the basis for the development of a blood-based
lung cancer diagnostic tool with very high sensitivity.
This new diagnostic tool may ultimately show clinical
utility in combination with current imaging techniques
by reducing the false positive rate of such methods and
has the potential for broader applications in deﬁnition of
the at-risk screening population.Control for stochastic sampling
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Xiaolu Zhang, Erin L. Crawford,
James C. Willey The University of Toledo Health Sciences
Campus, Toledo, OHBackground: Clinical implementation ofNext-Generation
Sequencing (NGS) for analysis of actionable mutations in
tumor tissues is challenged by poor control for stochastic
sampling, library preparation biases and qualitative
sequencing error. Potential sources of analytical variation
due to stochastic sampling include low number of analyte
copies loaded into library preparation and low number oflibrary amplicons loaded into sequencer. Sequence error
may be introduced by polymerase inﬁdelity during
ampliﬁcation in library preparation and/or sequencing
reaction. Inadequate control for these factors prevents
establishment of reliable lower detection threshold for
measurement of actionable mutations in cancer speci-
mens.We recently developed amultiplex competitive PCR
amplicon method for NGS library preparation that con-
trols for these sources of analytical variation (Blomquist et
al, 2013; Blomquist et al, 2015). Here we describe imple-
mentation of this method to determine lower limits for
reliable measurement of KRAS codons 12 and 13 muta-
tions in clinical samples.
Methods: DNA was extracted from FFPE samples con-
taining KRAS mutation and serially diluted relative to
FFPE-derived DNA without mutation. Each sample DNA
was mixed with a known number of synthetic internal
standard (IS) molecules for KRAS and multiple other
targets, then multiplex PCR-ampliﬁed using primers
spanning a 100 bp region for each target, including the
KRAS region containing codons 12 and 13 (nucleotide
positions 34-39). The PCR product for each sample was
then loaded onto a Fluidigm AccessArray and each target,
including KRAS, was ampliﬁed in a second round with
single target primers. Each second round PCR product
was loaded onto an Illumina HiSeq. Total KRAS molecule
copies (i.e., wild-type and mutated) were measured in
each sample relative to the known number of synthetic
internal standard copies. Conﬁdence limits for each value
(percent mutated) were calculated based on an equation
that controlled for number of copies loaded into library
preparation and library amplicons loaded into sequencer.
Technically-derived qualitative sequencing errors (i.e.,
base substitution, insertion and deletion) were measured
at each codon 12/13 base position in both a) KRAS native
template (NT) and b) synthetic IS. We previously deter-
mined that the frequency and type of sequence variation
at each base position within each IS is concordant with
that in respective NTs (r2 ¼ 0.93).
Results: For G>A mutations (e.g. 35-38G>A), the poly-
merase error frequency was about 0.1-0.3%. Thus, the
lower limit for reliable detection of a two-fold difference
would be above 0.5%. In contrast, for G>C mutations
error frequency was <0.01% and as long as 50,000
ampliﬁable KRAS copies are loaded (approximately 500
ng of FFPE sample) into library preparation, and given
sufﬁcient sequencing space/sample ratio, it would be
possible to reliably measure two-fold variation in frac-
tion as low as 0.05% with 95% conﬁdence.
Conclusion: The limit to lower detection of KRAS mu-
tation fraction is determined by a) number of ampliﬁable
mutated copies loaded into library preparation, b) num-
ber of library products loaded into sequencer, c) ratio of
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ase error at the nucleotide site bearing the mutation. In
targeted NGS, synthetic competitive IS control for sto-
chastic sampling at input of both target into library
preparation and of target library product into sequencer,
enable reduced sequencing space requirement, and con-
trol for qualitative errors generated during library
preparation and sequencing. These controls enable ac-
curate clinical diagnostic reporting of conﬁdence limits
and limit of detection for copy number measurement, and
reduce sequencing space required for analysis.Characteristics, oncogene dependency,
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Lung cancer is molecularly heterogeneous characterized
by various genetic alterations. Many targetable mutations
in lung adenocarcinoma occur at low frequencies, which
limits timely recruitment of patients in clinical trials of
precision therapy. Thus, preclinical animal models are
invaluable for evaluation of novel targeted drugs.
Recurrent RET fusions have been found in 1-2% of non-
small cell lung cancer (NSCLC). Among them KIF5B-RET
fusion is the most prevalent. To develop an animal model
for evaluation of KIF5B-RET fusion in lung adenocarci-
noma, we generated transgenic mice containing a doxy-
cycline-inducible tetO-KIF5B-RET transgene. Induction of
CCSP-rtTA/tetO-KIF5B-RET bitransgenic mice with
doxycycline resulted in MRI- and CT-detectable lung
adenocarcinoma in 4-5 months. KIF5B-RET-induced lung
adenocarcinoma is characterized by desmoplastic reac-
tion. Desmoplasia is associated with invasive lung
adenocarcinoma and is found in human RET-fusion-pos-
itive lung adenocarcinoma, but it has not been observed
in transgenic mouse models of EGFRL858R-, KrasG12D-, or
PTPN11E76K-induced lung adenocarcinoma. Using MRI,
CT, and histological examinations, we evaluated onco-
gene dependence and the response to the multikinase
RET inhibitor ponatinib in KIF5B-RET-induced lung tu-
mors. Tumors regressed one month after Dox withdrawal
or ponatinib treatment. Thus, we have established a
transgenic mouse model of KIF5B-RET-induced lung
adenocarcinoma. The KIF5B-RET-induced lung tumorsare associated with desmoplasia, dependent on KIF5B-
RET for maintaining the malignant phenotype, and
respond to ponatinib treatment.
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Mark W. Onaitis Duke University, Durham, NCWe have previously used cell lineage speciﬁc CreER mouse
models to identify Type II cells as the cell-of-origin of
KrasG12D induced lung adenocarcinoma.Using gain and loss
of function genetic models, we discovered the active Notch
signaling and low Sox2 dictate the ability of type II cells to
proliferate and progress into adenocarcinoma upon
KrasG12Dactivation.Hereweprovided further evidence that
Notch signaling is required for KrasG12D induced Type II
cells into a biopotent embryonic state. These SpcþRageþ
cells express speciﬁc lung embryonic development marker
Sox9 and Ezh2. Additionally, genetical and chemical Sox2
upregulation profoundly inhibits KrasG12D-induced lung
tumor formation inType II cells. Sox2-expressingType II cells
are unable to dedifferentiating Type II cells when Kras is
activated. Inconclusion,ourdatasuggestKrascanspeciﬁcally
transform Type II cells into lung adenocarcinoma by dedif-
ferentiating Type II cells into SpcþRageþ bipotent embry-
onic progenitor cells through activated Notch signaling.
Unregulated Sox2 can alter Type II cells to proximal cell state,
with subsequent loss of ability to dedifferentiate into these
bipotent embryonic cells. Our ﬁndings could provide a new
therapeutic strategy to target Kras activated lung cancer.ROR1 functions as a scaffold of
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